Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2015

View Archived Issues

Epic's CTC technology reveals actionable liquid biopsy biomarkers for prostate and bladder cancer

CPE gene null mutation linked to severe obesity and other disorders

New company Lattice Biotech advances biofilm disruption technology

New bioinformatics tool as a filtering strategy for bacterial vaccine discovery

Oxis Biotech licenses rights to antibody-drug conjugates for cancer

Samsung Bioepis submits MAA to EMA for Remicade biosimilar

FDA approves Saphris for pediatric patients with bipolar I disorder

Baxter BioScience reports phase III data for BAX-817 in hemophilia A and B

Fujian Haixi announces FFAR1 agonists

First patient treated in Japanese phase III study of NK-kappaB decoy oligonucleotide

Bayer Schering Pharma patents novel SERMs

Merck & Co. patents himbacine derivatives as PAR-1 antagonists

Pfizer executes collaborative research agreement with National Cancer Center

Novel Dynamic BH3 profiling shows potential for guiding patient care

Edaravone given U.S. orphan status for amyotrophic lateral sclerosis

The Vanderbilt University reports Mcl-1 inhibitors

St. Jude Children's Research Hospital patents endopeptidase Clp activators

Indian CSIR patents antitumor pyrazolochalcones

Immune Design studies combinatorial regimen CMB-305 for NY-ESO-1-expressing cancers

Bendavia fails to reduce infarct size in first-time STEMI patients

WuXi PharmaTech to build new cell therapy manufacturing facility

FDA grants Exjade orphan designation for chronic iron overload in alpha-thalassemia

Reolysin receives two new U.S. orphan drug designations

Population Genetics Technologies and Case Western Reserve University to test HIV drug resistance

FDA orphan drug status conferred on propranolol hydrochloride/etodolac for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...